Lumosa Therapeutics Co., Ltd.

NT$70.20As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6535Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR 2.49%
Div yield —
ROE (26.11%)
Biotechnology
Beta (5Y) 0.19
PE TTM —
TSR TTM (66.57%)
Mkt cap NT$11.76B
ROIC (13.13%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$71
1.30%
(79.51%)
Hold 10|3|1|10|6
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.90
0.87
0.87
0.97
7.40%
8.52%
3.83%
6.42%
RevenueNT$M
532.5
523.1
539.8
570.4
1.64%
0.50%
5.67%
9.50%
Peers (US$355.1M)
Cap (US$)
PE
356.5M
14.33x
Capital
TTM
5Y
10Y
Leveragex
0.089
0.940
0.804
EBIT/Intx
0.877
0.891
0.824
Own earn%
(8.78)
(72.63)
(66.11)
Sh yield%
56.20
28.25
29.57
Owners
Insiders/Inst%
1.27
58.24
Short interest%
2.48
SBC / revenue%
2.57
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
4
Op margin range%
9–16
$1 testx
—
Incr. ROIC%
3